Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMEN: 177Lu-octreotate in Refractory Neuroendocrine Tumours
NCT01842165Phase 3Completed
- Sponsor
- Institut Jules Bordet
- Start
- May 2013
- Primary completion
- Jan 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Institut Jules Bordet. Started May 2013; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT01842165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01842165.